Climate Change

■ CO₂ Emissions Trends

Trends of CO₂ emissions in Scope 1 and 2

We set long-term targets for CO₂ emissions and strive to continuously reduce the emissions. The trends of CO₂ emissions in Scope 1 and 2 over the past three years are shown below. Due to the absorption-type merger of Nagase Medicals Co., Ltd., CO₂ emissions from the Itami Plant have been added since FY2021. Even after deducting this effect, total CO₂ emissions increased slightly from FY2019 to FY2020, and increased in FY2021. We think that these increases were due to the launch of operation of the new high-potency manufacturing facility and an increase in contract manufacturing orders.

CO₂ emissions in Scope 3

CO₂ emissions in Scope 3 are higher than those in Scope 1 and 2. Future efforts are necessary to reduce these. (See “Supply Chain Management.”)

Scope 1: Direct greenhouse gas emissions by the reporting company itself (fuel combustion, industrial processes)

Scope 2: Indirect emissions associated with the use of electricity, heat, and steam supplied by other companies

Scope 3: Indirect emissions other than those in Scope 1 and 2 (emissions by other companies related to the company’s activities)

■ Biodiversity

As one of our efforts to contribute to environmental protection activities and the preservation of biodiversity, we are working with Suntory Holdings Limited to create original vending machines. By incorporating the project to conserve and manage threatened species and medicinal plants,^※1 conducted at the SHIONOGI Group’s Aburahi Botanical Gardens, and the Reforesting Kombu Project,^※2 conducted by Shionogi Healthcare Co., Ltd., into the designs of vending machines, we aim to visualize these projects and raise employee awareness by making them think about environmental conservation at random moments in their daily lives. We also donate part of the sales from the vending machines to related external environmental protection groups to contribute to resolving social issues.

TOPICS

■ Continuous Manufacturing

Continuous manufacturing of pharmaceuticals is a method that continuously manufactures products by feeding raw materials or their mixtures into the manufacturing process continuously while it is in operation. In general, the reasons why continuous manufacturing of pharmaceuticals (formulations) is required are as follows: (1) Since a scale-up study is unnecessary at the development stage, it is possible to reduce the amount of APIs and shorten the manufacturing process development period; (2) The use of Process Analytical Technology (PAT) and other tools makes it possible to monitor the manufacturing status, allowing for more reliable manufacturing; (3) The lot size can be changed flexibly, which contributes to securing a stable supply of pharmaceuticals and reducing the amount of product waste; and (4) Since manufacturing is possible with smaller equipment compared to batch manufacturing, it is possible to save space and energy and reduce CO₂ emissions.

The following diagram is an example of continuous manufacturing in which five processes from granulating to tableting are performed continuously in the tablet manufacturing process. Shionogi Pharma has actually applied for approval for continuous manufacturing with these five processes, has obtained approval, and has succeeded in their practical application.

● Reduction of the amount of APIs used

In our example, the adoption of continuous manufacturing enabled us to significantly reduce the amount of APIs necessary for a scale-up study (see the diagram below). This leads to a reduction in CO₂ emissions, equivalent to the amount of APIs that could be reduced, in the API manufacturing process.